Advertisement

Topics

FDA approves atezolizumab for NSCLC following platinum chemotherapy

10:54 EDT 19 Oct 2016 | ecancermedicalscience

On October 18, 2016, FDA approved atezolizumab (TECENTRIQ, Genentech Oncology) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with...

Original Article: FDA approves atezolizumab for NSCLC following platinum chemotherapy

NEXT ARTICLE

More From BioPortfolio on "FDA approves atezolizumab for NSCLC following platinum chemotherapy"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...